Birol Guvenc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Birol Guvenc has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Cagatay Unsal
Medical Faculty, Cukurova University
4 shared publications- Emel Gürkan
Department of Hematology, Faculty of Medicine, Çukurova University, 01330 Adana, Türkiye
3 shared publications Abdullah Canataroğlu
Division of Rheumatology-Imminology, Faculty of Medicine, Çukurova University, Balcali, 01330 Adana, Turkey
2 shared publicationsAyberk Besena
Medical Faculty, Cukurova University
1 shared publicationAydan Unsal
1 shared publication- Ayfer Gedük
Faculty of Medicine Hematology Clinic, Kocaeli University, Kocaeli 41380, Türkiye
1 shared publication
Latest Publications
- 26 June 2021
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 38 (2) , 299-308
The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
This study aimed to evaluate the clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndromes (MDS) in the real-life setting. A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion need were recorded before and during 12-month treatment. Hemoglobin levels were significantly higher at each follow up visit when compared to baseline levels in both epoetin alfa (mean ± SD 8.68 ± 1.0 g/dL at baseline vs. 9.83 ± 1.45, 9.99 ± 1.55, 10.24 ± 1.77 and 10.2 ± 1.5 g/dL, respectively) and darbepoetin alfa (8.83 ± 1.09 g/dL at baseline vs. 9.62 ± 1.37, 9.78 ± 1.49, 9.9 ± 1.39 and 10.1 ± 1.5 g/dL, respectively) groups (p < 0.001 for each). Transfusion need significantly decreased from baseline at each study visit in the epoetin alfa group (p < 0.001) and only at the 12th month visit (p < 0.001) in the darbepoetin alfa group. Hemoglobin levels or transfusion need was similar between treatment groups. Overall, 12-month response rate was 58.1% for epoetin alfa and 41.9% for darbepoetin alfa, with no significant difference between treatment groups, whereas higher response rate was noted within the first three months (62.7%) compared to next 9 months (ranged 44.4–60%) of treatment in the epoetin alfa group (p ranged 0.002 to < 0.001). This real-life retrospective study revealed similar efficacy of epoetin alfa and darbepoetin alfa among low risk or intermediate-1 risk MDS patients with no difference in treatment response between treatment groups, whereas a likelihood of earlier treatment response in the epoetin alfa group.
- 26 June 2021
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 38 (2) , 299-308
The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
This study aimed to evaluate the clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndromes (MDS) in the real-life setting. A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion need were recorded before and during 12-month treatment. Hemoglobin levels were significantly higher at each follow up visit when compared to baseline levels in both epoetin alfa (mean ± SD 8.68 ± 1.0 g/dL at baseline vs. 9.83 ± 1.45, 9.99 ± 1.55, 10.24 ± 1.77 and 10.2 ± 1.5 g/dL, respectively) and darbepoetin alfa (8.83 ± 1.09 g/dL at baseline vs. 9.62 ± 1.37, 9.78 ± 1.49, 9.9 ± 1.39 and 10.1 ± 1.5 g/dL, respectively) groups (p < 0.001 for each). Transfusion need significantly decreased from baseline at each study visit in the epoetin alfa group (p < 0.001) and only at the 12th month visit (p < 0.001) in the darbepoetin alfa group. Hemoglobin levels or transfusion need was similar between treatment groups. Overall, 12-month response rate was 58.1% for epoetin alfa and 41.9% for darbepoetin alfa, with no significant difference between treatment groups, whereas higher response rate was noted within the first three months (62.7%) compared to next 9 months (ranged 44.4–60%) of treatment in the epoetin alfa group (p ranged 0.002 to < 0.001). This real-life retrospective study revealed similar efficacy of epoetin alfa and darbepoetin alfa among low risk or intermediate-1 risk MDS patients with no difference in treatment response between treatment groups, whereas a likelihood of earlier treatment response in the epoetin alfa group.
- 2 January 2017
- Published by Kamla Raj Enterprises in International Journal of Human Genetics
- Vol. 17 (1) , 26-30
Major Histocompatibility Complex Class I-related Chain A and B Gene Expression in Sepsis Patient
Major histocompatibility complex class I-related chain A and B (MICA/B) function in the regulation of protective responses due to stress induced expression. One of the major causes of the morbidity is sepsis. The objective of this study was to measure the mRNA levels of these genes in the control and sepsis patient groups. Data showed increases in mRNA concentrations of MICA and MICB in the Patient Group in contrast to the Control Group. However this level was found higher than MICA mRNA concentration in the patient group. The current study is the first report according to the researchers’ knowledge representing the significant increases in the MICA and MICB expressions in the sepsis. This might provide a useful data for emphasizing these molecules as sensitive biomarkers. Further research is needed to enlighten the detail mechanisms of the MICA/B roles and to develop new treatment approaches.
- 2 January 2017
- Published by Kamla Raj Enterprises in International Journal of Human Genetics
- Vol. 17 (1) , 26-30
Major Histocompatibility Complex Class I-related Chain A and B Gene Expression in Sepsis Patient
Major histocompatibility complex class I-related chain A and B (MICA/B) function in the regulation of protective responses due to stress induced expression. One of the major causes of the morbidity is sepsis. The objective of this study was to measure the mRNA levels of these genes in the control and sepsis patient groups. Data showed increases in mRNA concentrations of MICA and MICB in the Patient Group in contrast to the Control Group. However this level was found higher than MICA mRNA concentration in the patient group. The current study is the first report according to the researchers’ knowledge representing the significant increases in the MICA and MICB expressions in the sepsis. This might provide a useful data for emphasizing these molecules as sensitive biomarkers. Further research is needed to enlighten the detail mechanisms of the MICA/B roles and to develop new treatment approaches.
- 24 March 2010
- Published by S. Karger AG in Acta Haematologica
- Vol. 123 (4) , 197-200
Molecular Characterization of α-Thalassemia in Adana, Turkey: A Single Center Study
Background/Aim: α-Thalassemia (α-thal) is a widespread genetic disorder throughout the world caused primarily by reduced synthesis of the α-globin chains, and it has been found at a high incidence in Turkey. Our aim in this study was to determine the frequency and molecular properties of α-thal in Adana, Turkey. Material and Methods: A total of 3,000 individuals comprising premarital couples or patients with anemia were screened between 2007 and 2008. Hematological parameters were analyzed using an automatic cell counter, and to detect the carriers of hemoglobin variants, high-performance liquid chromatography was used. Molecular screening of the α-globin gene was carried out by an Alpha-Globin StripAssay® which is based on multiplex PCR for specific amplification. Results: We have identified 225 cases with α-thal and found that the prevalence of α-thal is 7.5% in this area. In molecular analyses, the α-thal gene mutations α3.7, α4.2, --MED, --20.5, αPA-2α, αααanti-3.7, and αPA-1α were detected. Conclusion: Our results showed that the α-thal mutations represent a great heterogeneity and that the -α3.7 deletion has the highest frequency in Adana.
- 24 March 2010
- Published by S. Karger AG in Acta Haematologica
- Vol. 123 (4) , 197-200
Molecular Characterization of α-Thalassemia in Adana, Turkey: A Single Center Study
Background/Aim: α-Thalassemia (α-thal) is a widespread genetic disorder throughout the world caused primarily by reduced synthesis of the α-globin chains, and it has been found at a high incidence in Turkey. Our aim in this study was to determine the frequency and molecular properties of α-thal in Adana, Turkey. Material and Methods: A total of 3,000 individuals comprising premarital couples or patients with anemia were screened between 2007 and 2008. Hematological parameters were analyzed using an automatic cell counter, and to detect the carriers of hemoglobin variants, high-performance liquid chromatography was used. Molecular screening of the α-globin gene was carried out by an Alpha-Globin StripAssay® which is based on multiplex PCR for specific amplification. Results: We have identified 225 cases with α-thal and found that the prevalence of α-thal is 7.5% in this area. In molecular analyses, the α-thal gene mutations α3.7, α4.2, --MED, --20.5, αPA-2α, αααanti-3.7, and αPA-1α were detected. Conclusion: Our results showed that the α-thal mutations represent a great heterogeneity and that the -α3.7 deletion has the highest frequency in Adana.
- 1 August 2005
- Published by Springer Nature in International Journal of Hematology
- Vol. 82 (2) , 127-131
Renal Vascular Resistance in Sickle Cell Painful Crisis
Vaso-occlusive painful crisis is one of the characteristic manifestations of sickle cell disease (SCD). We aimed to investigate the state of renal vascular resistance by means of Doppler ultrasonography during vaso-occlusive painful crisis in patients with SCD. The 60 patients with homozygous SCD who entered the study were divided into 2 groups. Group 1 included 45 patients who were living in steady-state conditions and had no history of transfusions within the 3 months before the initiation of the study. Group 2 consisted of 15 patients with signs of painful vaso-occlusive crisis during evaluation. Group 2 patients had significant reductions in 3 measures of flow velocity in both main renal arteries, compared with group 1 patients (P < .04,P < .001, andP < .01). Mean and end-diastolic velocities in the segmental arteries (P < .01, andP < .001, respectively) and end-diastolic velocities in the interlobar arteries (P < .04) were lower in group 2 patients than in group 1 patients. Analysis of resistive (RI) and pulsatile (PI) indices in the investigated arteries demonstrated that the RI of the renal(P < .001;P < .0001), segmental(P < .002;P < .0001) and interlobar (P < .001;P < .0001) arteries of both kidneys in group 2 patients were significantly higher than the RI in group 1 patients and the control subjects, respectively. Total PI (P < .003;P < .0001) and total RI (P < .0001;P < .0001) for both kidneys were markedly higher in group 2 patients than in group 1 patients and the healthy subjects, respectively. Our preliminary results suggest a reduction of renal blood flow and an increase in renal vascular resistance during painful crisis compared with steady-state SCD.
- 1 August 2005
- Published by Springer Nature in International Journal of Hematology
- Vol. 82 (2) , 127-131
Renal Vascular Resistance in Sickle Cell Painful Crisis
Vaso-occlusive painful crisis is one of the characteristic manifestations of sickle cell disease (SCD). We aimed to investigate the state of renal vascular resistance by means of Doppler ultrasonography during vaso-occlusive painful crisis in patients with SCD. The 60 patients with homozygous SCD who entered the study were divided into 2 groups. Group 1 included 45 patients who were living in steady-state conditions and had no history of transfusions within the 3 months before the initiation of the study. Group 2 consisted of 15 patients with signs of painful vaso-occlusive crisis during evaluation. Group 2 patients had significant reductions in 3 measures of flow velocity in both main renal arteries, compared with group 1 patients (P < .04,P < .001, andP < .01). Mean and end-diastolic velocities in the segmental arteries (P < .01, andP < .001, respectively) and end-diastolic velocities in the interlobar arteries (P < .04) were lower in group 2 patients than in group 1 patients. Analysis of resistive (RI) and pulsatile (PI) indices in the investigated arteries demonstrated that the RI of the renal(P < .001;P < .0001), segmental(P < .002;P < .0001) and interlobar (P < .001;P < .0001) arteries of both kidneys in group 2 patients were significantly higher than the RI in group 1 patients and the control subjects, respectively. Total PI (P < .003;P < .0001) and total RI (P < .0001;P < .0001) for both kidneys were markedly higher in group 2 patients than in group 1 patients and the healthy subjects, respectively. Our preliminary results suggest a reduction of renal blood flow and an increase in renal vascular resistance during painful crisis compared with steady-state SCD.
- 1 June 2005
- Vol. 97 (6) , 820-2
Sickle cell anemia patient with sarcoidosis-associated inguinal lymph node and lung infiltration.
Sarcoidosis is a chronic, systemic inflammatory disease of unknown etiology, characterized by noncaseating granulomatous infiltration of any organ. Sickle cell anemia (SCA) is the homozygoid form of sickle cell disease (SCD), which includes a group of genetic disorders characterized by production of an abnormal hemoglobin S (HbS). There are a few case reports with coexistence of sarcoidosis and SCA. We reported a 47-year-old female with SCA and sarcoidosis.
- 1 June 2005
- Vol. 97 (6) , 820-2
Sickle cell anemia patient with sarcoidosis-associated inguinal lymph node and lung infiltration.
Sarcoidosis is a chronic, systemic inflammatory disease of unknown etiology, characterized by noncaseating granulomatous infiltration of any organ. Sickle cell anemia (SCA) is the homozygoid form of sickle cell disease (SCD), which includes a group of genetic disorders characterized by production of an abnormal hemoglobin S (HbS). There are a few case reports with coexistence of sarcoidosis and SCA. We reported a 47-year-old female with SCA and sarcoidosis.
- 1 August 2004
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 31 (1) , 17-20
Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report
- 1 August 2004
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 31 (1) , 17-20
Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report
- 5 March 2004
- Vol. 21 (1) , 27-32
Anti-D and Intravenous Immunoglobulin Treatments in Chronic Idiopathic Thrombocytopenic Purpura.
The aim of this prospective study was to evaluate the data from 29 patients diagnosed as chronic refractory idiopathic thrombocytopenic purpura (ITP) treated with anti-D immunoglobulin and intravenous immunoglobulin G (IVIG). We used anti-D and IVIG in 11 and 18 patients respectively in whom the previous treatments including corticosteroids and splenectomy had been unsuccessful. The complete response rates were significantly higher in IVIG arm (55.5% to 18.1%) with a duration of 8 weeks. The overall efficacy of IVIG in the chronic ITP is similar to previous data, however we found lower platelet responses in patients treated with anti-D that can be attributed to the lower sucess in the splenectomized patients.
- 5 March 2004
- Vol. 21 (1) , 27-32
Anti-D and Intravenous Immunoglobulin Treatments in Chronic Idiopathic Thrombocytopenic Purpura.
The aim of this prospective study was to evaluate the data from 29 patients diagnosed as chronic refractory idiopathic thrombocytopenic purpura (ITP) treated with anti-D immunoglobulin and intravenous immunoglobulin G (IVIG). We used anti-D and IVIG in 11 and 18 patients respectively in whom the previous treatments including corticosteroids and splenectomy had been unsuccessful. The complete response rates were significantly higher in IVIG arm (55.5% to 18.1%) with a duration of 8 weeks. The overall efficacy of IVIG in the chronic ITP is similar to previous data, however we found lower platelet responses in patients treated with anti-D that can be attributed to the lower sucess in the splenectomized patients.
- 1 January 2004
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 19 (3) , 148-150
Plasmapheresis in the treatment of hyperthyroidism associated with agranulocytosis: A case report
Plasmapheresis, also known as therapeutic plasma exchange, is used in the treatment of several disorders. Temporary improvement after plasmapheresis in cases with thyrotoxicosis has been reported. A 55‐year‐old woman presented with agranulocytosis induced by propylthiouracil and clinical signs of heart failure. Three sessions of plasmapheresis were performed. We observed an improvement of thyroid hormone levels and clinical findings as well. Plasmapheresis can be an option when drug treatment of thyrotoxicosis fails. J. Clin. Apheresis 19:148–150, 2004.
- 1 January 2004
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 19 (3) , 148-150
Plasmapheresis in the treatment of hyperthyroidism associated with agranulocytosis: A case report
Plasmapheresis, also known as therapeutic plasma exchange, is used in the treatment of several disorders. Temporary improvement after plasmapheresis in cases with thyrotoxicosis has been reported. A 55‐year‐old woman presented with agranulocytosis induced by propylthiouracil and clinical signs of heart failure. Three sessions of plasmapheresis were performed. We observed an improvement of thyroid hormone levels and clinical findings as well. Plasmapheresis can be an option when drug treatment of thyrotoxicosis fails. J. Clin. Apheresis 19:148–150, 2004.